Gardo

Garda Therapeutics is an emerging pharmaceutical company focused on acquiring and optimizing mid-sized specialty assets to enhance patient outcomes. The company's strategy involves identifying underutilized or underappreciated therapeutic assets, particularly in the oncology space, and maximizing their market value through strategic investment and development. Garda's leadership team has significant experience in the life sciences sector, including successful track records at companies like Secura Bio and Prometheus Laboratories. Currently, the company manages a portfolio that includes assets previously acquired from major pharmaceutical firms, targeting both hematologic and solid tumors. Garda Therapeutics aims to drive innovation by procuring proprietary, growable assets via product acquisitions or licensing opportunities.